Ocugen Announces Dosing Completion of Subjects with Geograph

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410-A Modifier Gene Therapy

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410-A Modifier Gene Therapy

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Americans , Syedm Shah , , Head Of Communications , Retina Service At Gundersen Health System , Exchange Commission , Ocugen Inc , Linkedin , Announces Dosing Completion , Geographic Atrophy , Mada Clinical Trial , Modifier Gene , Huma Qamar , Chief Medical Officer , Vice Chair , Digital Medicine , Retina Service , Gundersen Health System , Safety Monitoring Board , Narmada Phase , Orphan Receptor , Private Securities Litigation Reform Act ,